Table 1

Clinical characteristics of the randomized patient groups

Characteristic

977A

977B

Number

%

Number

%


Age at diagnosis (years)

≤ 40

89

9

80

8

41-50

197

20

207

21

> 50

494

51

492

50

unknown

197

20

198

20

Distant metastasis-free survival (years)

no recurrence, < 5

617

63

648

66

recurrence, < 5

198

20

184

19

lost to follow-up, < 5

111

11

96

10

no recurrence, 5-to 10

245

25

253

26

recurrence, 5 to 10

51

5

49

5

lost to follow-up, 5 to 10

357

37

395

40

Estrogen receptor status

positive

657

67

686

70

negative

220

23

181

19

unknown

100

10

110

11

Lymph node status

negative

749

77

749

77

positive

217

22

220

23

unknown

11

1

8

1

Histologic grade

well differentiated

105

11

131

13

moderately differentiated

317

31

335

34

poorly differentiated

316

32

260

27

unknown

239

24

251

26

Tumor size (cm)

≤ 2.0

482

49

505

52

2.1 to 5.0

363

37

356

36

> 5.0

29

3

19

2

unknown

103

11

97

10

Adjuvant treatment

yes

478

49

488

50

no

490

50

484

50

tamoxifen monotherapy (ER+)

318

33

332

34

chemotherapy

141

14

140

14

unknown

9

1

5

1

Molecular subtypes

Basal

243

25

217

22

HER2-E

93

10

81

8

Claudin-Low

48

5

44

5

Luminal A

264

27

303

31

Luminal B

185

19

188

19


ER+: Estrogen receptor-positive breast cancer; HER2-E: human epidermal growth factor receptor 2-enriched.

Nagalla et al. Genome Biology 2013 14:R34   doi:10.1186/gb-2013-14-4-r34

Open Data